目的 缺血性脑血管病患者接受脑苷肌肽治疗的临床效果及对患者神经功能的影响。方法 选取我院2015年8月至 2017年2月收治的80例缺血性脑血管病患者为研究对象，依据治疗方法将这些患者分为研究组(n=40例)与对照组 (n=40例)，对照组单独采用血塞通注射液治疗，研究组行血塞通注射液联合脑苷肌肽治疗，对比2组患者临床治疗 效果及NIHSS评分情况。结果 治疗前研究组与对照组NIHSS评分之间的差异无统计学意义(P>0.05)。组内比较，和 治疗前相比，2组患者治疗后NIHSS评分均有所降低，且研究组治疗后NIHSS评分低于对照组，研究组(92.5%)治疗效 果优于对照组(75%)，组间数据对比差异有统计学意义(P<0.05)。研究组不良反应发生率为10.0%，对照组为5.0%， 差异无统计学意义(P>0.05)。结论 缺血性脑血管病患者接受脑苷肌肽治疗效果好，能够有效改善患者的神经功 能，值得在临床推广使用。

Objective To observe the clinical effect of cerebroside glycoside and Carnosine in patients with ischemic cerebrovascular disease and its effect on neurological function. Methods 80 patients with ischemic cerebrovascular disease treated in our hospital from August 2015 to February 2017 were selected. according to the treatment, the patients were divided into study group (n=40 cases) and control group (n=40 cases), the control group was treated by Xuesaitong injection, the study group was treated by Xuesaitong injection combined with cattle cerebroside glycoside and carnosine treatment, the clinical effect and NIHSS score were compared. Results There was no significant difference between the study group and the control group before treatment (P>0.05). The NIHSS score in group 2 after treatment was lower than that in the control group, and the study group (92.5%) was better than the control group (75%). the difference between the two groups was significant (P<0.05 ). The incidence of adverse reaction was 10.0 % in the study group and 5.0 % in the control group, the difference was not significant (P>0.05). Conclusion The patients with ischemic cerebrovascular disease receive cerebroside glycoside and Carnosine, which can effectively improve the neurological function of patients, and it is worth to be used in clinical practice.